8-KItem 2.02 · Results of OperationsItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements
Regeneron filed an 8‑K (1/12/26) attaching Exhibit 99.1 — a Jan 12, 2026 presentation by CEO Leonard S.
Filed with the SEC on · Summarized by InvestorsBot
Regeneron filed an 8‑K (1/12/26) attaching Exhibit 99.1 — a Jan 12, 2026 presentation by CEO Leonard S. Schleifer and CSO George D. Yancopoulos at the 44th J.P. Morgan Healthcare Conference. 📊 $REGN #Regeneron #JPMHealthcare
The 8‑K discloses Regeneron expects an acquired in‑process R&D charge for the quarter ended Dec 31, 2025 and that it will impact GAAP and non‑GAAP diluted EPS; no dollar amount provided. ⚠️ $REGN #investing #biotech
Filing reiterates use of non‑GAAP net income per diluted share for guidance/analysis, notes limitations and tax adjustments; cover page XBRL included. Presentation available as Exhibit 99.1. 📄 $REGN #Finance #Healthcare